Jack Arnold, MBBS, MRCP, PhD

Laurence Duquenne, MD, PhD, joins Joint Ventures to discuss the TEEMS trial and T-cell stratification.

Novel CAR-T approaches targeting both CD19 and BCMA signal a paradigm shift in systemic sclerosis, alongside a growing focus on early diagnosis.

Hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, preview the sessions, themes, and abstracts they are most excited about heading into the meeting in London.

Lucy Carter, MBBS, PhD, and our hosts continue their discussion on the journey of B-cell depletion.

Lucy Carter, MBBS, PhD, joins our hosts to discuss how B-cell therapies have evolved for rheumatic disease.

Jack Arnold, MBBS, PhD, and Rihards Buss, MD, discuss early investigations of GLP-1 RAs in rheumatoid arthritis and lupus.

Jack Arnold, MBBS, PhD, and Rihards Buss, MD, discuss the growing use of GLP-1 RAs in the rheumatology field.

Rihards Buss, MD, and Jack Arnolds, MBBS, PhD, discussed the latest data on nipocalimab in lupus and deucravacitinib for PsA.

Joint Ventures is a rheumatology podcast from RheumatologyLive hosted by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, exploring the latest news and research in the field.

Anxiety and depression can limit engagement with healthcare or treatment leading to later diagnosis, poor treatment adherence, and poor disease control with associated negative sequelae.

Findings demonstrate the utility of machine learning in aiding clinical risk stratification within a complex patient cohort.

In SLE, higher doses of prednisolone and the use of immunosuppressive agents, such as cyclophosphamide, have been associated with higher rates of infective sequelae.

As treatment options expand in SLE with an increasing number of targeted therapeutics, we can be optimistic about the potential to improve disease outcomes.

The utility of calculating interferon scores in SLE has generated considerable discourse amongst rheumatologists.

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

Telemedicine is an evolving and helpful tool in how rheumatologists manage their outpatient cohort. However, careful distinction of who can continue to be managed remotely is crucial.

Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.

With several targeted therapies demonstrating positive trial results in lupus nephritis, the treatment paradigm appears to be shifting.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."